AEterna Zentaris shares declined 22.52 percent on volume of over 4.3 million shares traded Monday to close at $2.03 a share. The company announced it has been recommended to discontinue its Phase 3 trial of its multiple myeloma treatment.
Going forward ... (see research report)
Copyright ® 2013. The Bedford Report. All Rights Reserved.